**An Overview of Important Genetic Aspects in Melanoma**

Rohinton S. Tarapore

[29] Sapoznik, S, Faranseh, S, Ortenberg, R, Hamburger, T, Barak, V, Peretz, T, Schachter, J, Markel, G, & Lotern, M. Serum CEACAM-1 correlates with disease progression

[30] Shinozaki, M, Day, O, Kitago, S. J, Amersi, M, Kuo, F, Kim, C, & Wang, J. HJ, Hoon DSB. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma

[31] Bouwhuis, M. G, Suciu, S, Kruit, W, Sales, F, Stoitchkov, K, Patel, P, Cocuyt, V, Tho‐ mas, J, Liénard, D, Eggermont, A. M, & Ghanem, G. Prognostic value of serial blood S100B dterminations in stage IIB-III melanoma patients : a corollary study for the

[32] Butterfield, L. H, Potter, D. M, & Kirkwood, J. M. Multiplex serum biomarkers as‐ sessments : technical and biostatistical issues. J Transl Med (2011). Oct 11 ; 9 : 173.

patients receiving biochemotherapy. Clin Cancer Res (2007). , 13(7), 2068-74.

EORTC trial 18952. Eur J Cancer (2011). , 47(3), 361-8.

42 Highlights in Skin Cancer

and survival in malignant melanoma patients. Clin Dev Immunol (2012).

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/55257
